Media & Resources

The International AIDS Vaccine Initiative (IAVI) congratulates its Board Chair, Dr. Alex Godwin Coutinho, on receiving an honorary doctorate degree from the University of Zurich’s (UZH) Medical Faculty. The degree recognizes the Ugandan medical doctor and global HIV/AIDS champion for his outstanding achievements in treatment and prevention. Coutinho is the former Executive Director of the…

NEW YORK – An IAVI-led team of scientists has defined an additional way to generate trimers from the major HIV subtypes A, B and C, with scalable properties that could benefit future clinical development of HIV vaccine candidates designed to elicit broadly neutralizing antibodies. The trimer is the critical target on the surface of HIV…

NEW YORK – Margaret McGlynn will step down after four years as President and CEO of the International AIDS Vaccine Initiative (IAVI). A search for her successor is underway, led by IAVI’s Board of Directors. “Margie’s outstanding experience as head of Merck global vaccines and her unique blend of professionalism and dedication have strongly positioned…

IAVI welcomes the promising results that Michael Farzan and his team have achieved by constructing an artificial protein that potently blocked HIV and SIV in vitro and protected against SHIV challenge in monkeys. These findings complement other ongoing studies aimed at designing prevention approaches that can work across the enormous diversity of HIV, and further…

New findings inform prevention, treatment and cure research and development.

NEW YORK – The International AIDS Vaccine Initiative (IAVI) has received a grant of US$350,000 from GSK to support implementation of the Human Vaccines Project, a new public-private partnership seeking to transform global disease prevention by collaboratively addressing some of the key scientific challenges in vaccine development across diseases. The GSK grant will help to establish…

The International AIDS Vaccine Initiative (IAVI) is pleased to announce that Dr. Moncef Slaoui, Chairman, Vaccines, GSK, has joined its Board of Directors. “Moncef Slaoui brings a wealth of experience in translating promising research into practical vaccines for use throughout the world,” said IAVI President and CEO Margie McGlynn. “His counsel will be crucial to…

Group’s Grant to IAVI Will Support AIDS Vaccine Research in Asia and Globally.